News

Arhalofenate is a uricosuric agent, when used in combination with xanthine oxidase inhibitors could be a treatment option for patients with tophaceous gout, a chronic, progressive rheumatic disease.

The partnership designates IGI as the developer and manufacturer of a family of prescription topical drug products owned by Medimetriks. In addition, as part of this long term

Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix under the trademark YouDerm Emtrix. Moberg Derma president and CEO Peter Wolpert said

SB12 is an oral care agent for bad breath. Meda has established SB12 in the Nordic region. In 2012, Meda intends to launch SB12 in about ten markets

The product comprises a blend of various ingredients including orange pekoe extract, green tea extract, black tea extract, hibiscus flower powder and Malva sylvestris extract. According to the

Under the agreement, the company will provide community oncology practices with better access to oral oncology drugs, clinical programs and adherence-enhancing medication management programs. RainTree Oncology president and

Under the collaboration, the combination of Merck’s proprietary RSV antigen will be evaluated with NanoBio’s NanoStat adjuvant technology, for use as an intranasal vaccine. As per the deal,

The new prostate formula is developed using the Nature’s Bioceuticals’ kidney formula as a base and adding a number of additional natural ingredients which target the prostate gland.

The University of Utah will manufacture certain materials derived from stem cells, as per the agreement. The University of Utah Clinical Regenerative Medicine and Tissue Engineering director Amit